Transcranial photobiomodulation increases cognition and serum BDNF levels in adults over 50 years: A randomized, double-blind, placebo-controlled trial

IF 3.9 2区生物学 Q2 BIOCHEMISTRY & MOLECULAR BIOLOGY

Journal of photochemistry and photobiology. B, Biology Pub Date : 2024-10-05 DOI:10.1016/j.jphotobiol.2024.113041

Bruna H. de Oliveira , Elisa F. Lins , Naiara F. Kunde , Afonso S.I. Salgado , Leidiane M. Martins , Franciane Bobinski , Willians F. Vieira , Paolo Cassano , Anna Quialheiro , Daniel F. Martins

{"title":"Transcranial photobiomodulation increases cognition and serum BDNF levels in adults over 50 years: A randomized, double-blind, placebo-controlled trial","authors":"Bruna H. de Oliveira , Elisa F. Lins , Naiara F. Kunde , Afonso S.I. Salgado , Leidiane M. Martins , Franciane Bobinski , Willians F. Vieira , Paolo Cassano , Anna Quialheiro , Daniel F. Martins","doi":"10.1016/j.jphotobiol.2024.113041","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>There is a significant lack of therapeutic options for mild cognitive impairment (MCI), which is rapidly becoming a global epidemic due to aging. Transcranial photobiomodulation (t-PBM) involves delivering near-infrared light (NIR) to the scalp, targeting cortical areas of the brain. NIR t-PBM has recently emerged as a potential therapy for various neurodegenerative conditions, including memory issues.</div></div><div><h3>Aims</h3><div>This study aimed to evaluate cognition scores (primary outcome), depression, anxiety, resilience scores, neuroplasticity, and neurodegeneration biomarkers (secondary outcomes) in individuals with MCI undergoing t-PBM therapy or receiving a placebo.</div></div><div><h3>Materials and Methods</h3><div>A total of 93 older adult individuals with MCI were randomly assigned to either a t-PBM (<em>n</em> = 47) or Placebo (<em>n</em> = 46) group. Clinical assessments were conducted at baseline, 60 days post-treatment, and a 150-day follow-up. We also measured serum levels of brain-derived neurotrophic factor (BDNF), a neuroplasticity biomarker, as well as neuron-specific enolase (NSE) and calcium-binding protein B (S100B), which are neurodegeneration biomarkers. Intervention effects were analyzed using repeated measures (RM) two-way ANOVA followed by Tukey post hoc test. Fischer's exact test and Generalized Estimating Equations (GEE) were also applied.</div></div><div><h3>Results</h3><div>Of the 93 older adults individuals invited to participate, 76 (t-PBM: 40, placebo: 36) completed the study. The t-PBM significantly improved cognition as measured by the Montreal Cognitive Assessment (MoCA) compared to placebo (<em>p</em> = 0.0301). The delta values for MoCA scores were 3.20 in the t-PBM group and 1.97 in the placebo group. This effect persisted until the three-month follow-up, accompanied by increased BDNF levels in the t-PBM group but not in the placebo group (<em>p</em> = 0.0046). The delta values for BDNF were 821.94 in the t-PBM group and 359.41 in the placebo group. t-PBM did not alter depression, anxiety, resilience scores, nor the levels of NSE and S100B in individuals with MCI.</div></div><div><h3>Conclusion</h3><div>The t-PBM increases cognitive function and BDNF levels in adults with MCI. Its application as an adjunctive treatment may play a crucial role in preventing neurodegenerative diseases.</div></div>","PeriodicalId":16772,"journal":{"name":"Journal of photochemistry and photobiology. B, Biology","volume":"260 ","pages":"Article 113041"},"PeriodicalIF":3.9000,"publicationDate":"2024-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of photochemistry and photobiology. B, Biology","FirstCategoryId":"99","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S101113442400201X","RegionNum":2,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background

There is a significant lack of therapeutic options for mild cognitive impairment (MCI), which is rapidly becoming a global epidemic due to aging. Transcranial photobiomodulation (t-PBM) involves delivering near-infrared light (NIR) to the scalp, targeting cortical areas of the brain. NIR t-PBM has recently emerged as a potential therapy for various neurodegenerative conditions, including memory issues.

Aims

This study aimed to evaluate cognition scores (primary outcome), depression, anxiety, resilience scores, neuroplasticity, and neurodegeneration biomarkers (secondary outcomes) in individuals with MCI undergoing t-PBM therapy or receiving a placebo.

Materials and Methods

A total of 93 older adult individuals with MCI were randomly assigned to either a t-PBM (n = 47) or Placebo (n = 46) group. Clinical assessments were conducted at baseline, 60 days post-treatment, and a 150-day follow-up. We also measured serum levels of brain-derived neurotrophic factor (BDNF), a neuroplasticity biomarker, as well as neuron-specific enolase (NSE) and calcium-binding protein B (S100B), which are neurodegeneration biomarkers. Intervention effects were analyzed using repeated measures (RM) two-way ANOVA followed by Tukey post hoc test. Fischer's exact test and Generalized Estimating Equations (GEE) were also applied.

Results

Of the 93 older adults individuals invited to participate, 76 (t-PBM: 40, placebo: 36) completed the study. The t-PBM significantly improved cognition as measured by the Montreal Cognitive Assessment (MoCA) compared to placebo (p = 0.0301). The delta values for MoCA scores were 3.20 in the t-PBM group and 1.97 in the placebo group. This effect persisted until the three-month follow-up, accompanied by increased BDNF levels in the t-PBM group but not in the placebo group (p = 0.0046). The delta values for BDNF were 821.94 in the t-PBM group and 359.41 in the placebo group. t-PBM did not alter depression, anxiety, resilience scores, nor the levels of NSE and S100B in individuals with MCI.

Conclusion

The t-PBM increases cognitive function and BDNF levels in adults with MCI. Its application as an adjunctive treatment may play a crucial role in preventing neurodegenerative diseases.

查看原文本刊更多论文

经颅光生物调节可提高 50 岁以上成年人的认知能力和血清 BDNF 水平：随机、双盲、安慰剂对照试验

背景由于老龄化的加剧，轻度认知障碍（MCI）正迅速成为一种全球性流行病，但目前却严重缺乏治疗方法。经颅光生物调控（t-PBM）是指将近红外线（NIR）照射到头皮上，以大脑皮层区域为目标。本研究旨在评估接受经颅光生物调节疗法或安慰剂治疗的 MCI 患者的认知评分（主要结果）、抑郁、焦虑、恢复力评分、神经可塑性和神经变性生物标志物（次要结果）。材料与方法93 名患有 MCI 的老年人被随机分配到经颅光生物调节疗法组（47 人）或安慰剂组（46 人）。分别在基线、治疗后 60 天和 150 天的随访中进行临床评估。我们还测量了血清中脑源性神经营养因子（BDNF）（神经可塑性生物标志物）以及神经元特异性烯醇化酶（NSE）和钙结合蛋白 B（S100B）（神经变性生物标志物）的水平。干预效果采用重复测量（RM）双向方差分析，然后进行Tukey事后检验。结果在受邀参加研究的 93 名老年人中，76 人（t-PBM：40 人，安慰剂：36 人）完成了研究。与安慰剂相比，t-PBM能明显改善蒙特利尔认知评估（MoCA）的认知能力（p = 0.0301）。t-PBM组的MoCA评分的delta值为3.20，安慰剂组为1.97。这种效应一直持续到三个月的随访，t-PBM 组的 BDNF 水平有所提高，而安慰剂组则没有（p = 0.0046）。t-PBM没有改变MCI患者的抑郁、焦虑、恢复力评分，也没有改变NSE和S100B的水平。结论t-PBM能提高MCI成人患者的认知功能和BDNF水平，作为一种辅助治疗方法，它可能在预防神经退行性疾病方面发挥重要作用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of photochemistry and photobiology. B, Biology 生物-生化与分子生物学

CiteScore

12.10

自引率

1.90%

发文量

161

审稿时长

37 days

期刊介绍： The Journal of Photochemistry and Photobiology B: Biology provides a forum for the publication of papers relating to the various aspects of photobiology, as well as a means for communication in this multidisciplinary field. The scope includes: - Bioluminescence - Chronobiology - DNA repair - Environmental photobiology - Nanotechnology in photobiology - Photocarcinogenesis - Photochemistry of biomolecules - Photodynamic therapy - Photomedicine - Photomorphogenesis - Photomovement - Photoreception - Photosensitization - Photosynthesis - Phototechnology - Spectroscopy of biological systems - UV and visible radiation effects and vision.